# US 8,278,353 B2 · Enhanced bimatoprost ophthalmic solution

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 8,278,353 B2
- Document ID: US8278353B2
- Status: Granted
- Kind: B2
- Application number: 13/370,574
- Filed: 2012-02-10
- Published: 2012-06-07
- Granted: 2012-10-02
- Earliest claimed: 2005-03-16
- Assignees: Allergan, Inc.
- Inventors: Chin-Ming Chang; James N. Chang; Rhett M. Schiffman; R. Scott Jordan; Joan-En Chang-Lin
- Web page: https://patentgrep.com/patent/US8278353B2

## CPC

- A61K 31/5575: having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
- A01N 33/12: Quaternary ammonium compounds
- A61K 9/0048: {Eye, e.g. artificial tears}
- A61K 31/14: Quaternary ammonium compounds, e.g. edrophonium, choline (betaines A61K31/205)
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/557: Eicosanoids, e.g. leukotrienes {or prostaglandins}
- A61K 47/02: Inorganic compounds
- A61K 47/12: Carboxylic acids; Salts or anhydrides thereof
- A61P 27/02: Ophthalmic agents
- A61P 27/06: Antiglaucoma agents or miotics
- A61P 27/14: Decongestants or antiallergics
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A01N: PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF (preservation of food or foodstuff A23); BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES (preparations for medical, dental or toiletry purposes which kill or prevent the growth or proliferation of unwanted organisms A61K); PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

A composition comprising from 0.005% to 0.02% bimatoprost by weight and from 100 ppm to 250 ppm benzalkonium chloride, wherein said composition is an aqueous liquid which is formulated for ophthalmic administration is disclosed herein.

## Claims

### Claim 1

A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure and results in less hyperemia as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

### Claim 2 (depends on 1)

The composition of claim 1 wherein the first composition has a pH of about 7.3.

### Claim 3 (depends on 1)

The composition of claim 1 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.

### Claim 4 (depends on 1)

The composition of claim 1 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA.

### Claim 5 (depends on 1)

The composition of claim 1 wherein the first composition is effective in treating glaucoma.

### Claim 6 (depends on 1)

The composition of claim 1 wherein the first composition is effective in treating ocular hypertension.

### Claim 7

A first composition administered once daily for lowering intraocular pressure in a person with glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the first composition lowers intraocular pressure without a substantial reduction in the intraocular pressure lowering benefit provided by the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

### Claim 8 (depends on 7)

The composition of claim 7 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.

### Claim 9 (depends on 7)

The composition of claim 7 wherein the first composition has a pH of about 7.3.

### Claim 10 (depends on 7)

The composition of claim 7 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.

### Claim 11 (depends on 7)

The composition of claim 7 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA.

### Claim 12 (depends on 7)

The composition of claim 7 wherein the first composition is applied topically.

### Claim 13 (depends on 7)

The composition of claim 7 wherein the first composition is effective in treating glaucoma.

### Claim 14 (depends on 7)

The composition of claim 7 wherein the first composition is effective in treating ocular hypertension.

### Claim 15

A first composition for reducing the amount of bimatoprost administered to a person in a once daily treatment for glaucoma or ocular hypertension, the first composition comprising about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein first the composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

### Claim 16 (depends on 15)

The composition of claim 15 wherein the once daily administration of the first composition results in less hyperemia as compared to the once daily administration of the second composition.

### Claim 17 (depends on 15)

The composition of claim 15 wherein the first composition has a pH of about 7.3.

### Claim 18 (depends on 15)

The composition of claim 15 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.

### Claim 19 (depends on 15)

The composition of claim 15 wherein the first composition is a solution.

### Claim 20 (depends on 15)

The composition of claim 15 wherein the first composition is effective in treating glaucoma.

### Claim 21 (depends on 20)

The composition of claim 20 wherein the glaucoma is open-angle glaucoma.

### Claim 22 (depends on 15)

The composition of claim 15 wherein the first composition is effective in treating ocular hypertension.

### Claim 23

A first composition for reducing the amount of bimatoprost administered to a person in a once daily treatment for glaucoma or ocular hypertension, wherein the first composition comprises about 0.01% w/v bimatoprost and about 0.02% w/v benzalkonium chloride, wherein the benzalkonium chloride concentration of the first composition increases the permeability of bimatoprost across corneal epithelial cell layers as compared to the once daily administration of a second composition comprising 0.03% w/v bimatoprost and 0.005% w/v benzalkonium chloride.

### Claim 24 (depends on 23)

The composition of claim 23 wherein the first composition remains useful in treating glaucoma or ocular hypertension despite a lower concentration of bimatoprost as compared to the second composition.

### Claim 25 (depends on 23)

The composition of claim 23 wherein the first composition results in less hyperemia as compared to the once daily administration of the second composition.

### Claim 26 (depends on 23)

The composition of claim 23 wherein the first composition is effective in treating glaucoma.

### Claim 27 (depends on 23)

The composition of claim 23 wherein the composition is effective in treating ocular hypertension.

### Claim 28 (depends on 23)

The composition of claim 23 wherein the first composition has a pH of about 7.3.

### Claim 29 (depends on 23)

The composition of claim 23 wherein the first composition has at least one buffering agent selected from the group consisting of dibasic sodium phosphate heptahydrate, citric acid monohydrate and EDTA.

### Claim 30 (depends on 23)

The composition of claim 23 wherein the first composition comprises 0.01% w/v bimatoprost and 0.02% w/v benzalkonium chloride.
